BridgeBio focuses on the development and commercialization of precision medicines for various genetic diseases and cancers.
BridgeBio has raised $1.0B in total funding. The most recent round was Post-IPO Equity. The last funding was announced in July 2026.
BridgeBio's investors include Sequoia Capital, Sixth Street, Perceptive Advisors, Blue Owl, Kohlberg Kravis Roberts & Co..
BridgeBio is headquartered in Palo Alto, United States.
BridgeBio focuses on the development and commercialization of precision medicines for various genetic diseases and cancers.
BridgeBio is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"BridgeBio — Funding & Investors." VCBacked, July 1, 2026, https://www.vcbacked.co/company/bridgebio. Accessed September 29, 2026.
VCBacked. (2026). BridgeBio — Funding & Investors. Retrieved September 29, 2026, from https://www.vcbacked.co/company/bridgebio
{{cite web |title=BridgeBio — Funding & Investors |url=https://www.vcbacked.co/company/bridgebio |website=VCBacked |access-date=September 29, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated